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Serotonin N-acetyltransferase (AANAT) converts serotonin
to N-acetylserotonin (NAS), a distinct biological regulator and
the immediate precursor of melatonin, a circulating hormone
that influences circadian processes, including sleep. N-terminal
sequences of AANAT enzymes vary among vertebrates. Mecha-
nisms that regulate the levels of AANAT are incompletely
understood. Previous findingswere consistentwith the possibil-
ity that AANAT may be controlled through its degradation by
the N-end rule pathway. By expressing the rat and human
AANATs and their mutants not only in mammalian cells but
also in the yeast Saccharomyces cerevisiae, and by taking advan-
tage of yeast genetics, we show here that two “complementary”
forms of rat AANAT are targeted for degradation by two “com-
plementary” branches of the N-end rule pathway. Specifically,
the N-terminally acetylated (Nt-acetylated) Ac-AANAT is
destroyed through the recognition of its Nt-acetylated N-termi-
nalMet residue by theAc/N-end rule pathway,whereas thenon-
Nt-acetylated AANAT is targeted by the Arg/N-end rule path-
way, which recognizes the unacetylated N-terminal Met-Leu
sequence of rat AANAT. We also show, by constructing lysine-
to-argininemutants of ratAANAT, that its degradation ismedi-
ated bypolyubiquitylationof its Lys residue(s).HumanAANAT,
whose N-terminal sequence differs from that of rodent
AANATs, is longer-lived than its rat counterpart and appears to
be refractory to degradation by the N-end rule pathway.
Together, these and related results indicate both a major
involvement of the N-end rule pathway in the control of rodent
AANATs and substantial differences in the regulation of rodent
and human AANATs that stem from differences in their N-ter-
minal sequences.
Arylalkylamine N-acetyltransferase (AANAT)2 converts
the neurotransmitter serotonin to N-acetylserotonin (NAS)
(1–11). Regulatory functions of NAS include its activity as an
agonist of TrkB, the receptor for the brain-derived neu-
rotrophic factor (12–14). NAS is the immediate precursor of
melatonin, a circulating hormone that regulates sleep and other
circadian processes in vertebrates. Melatonin is also present in
invertebrates, including insects, as well as in animals that lack
recognizable neurons (1, 15–21). The functions ofmelatonin in
mammals include the modulation of circadian rhythms in
response to light-dark cycles. Melatonin also contributes to the
control of seasonal physiology (20). These mechanisms are a
part of a broader range of processes that involve distinct biolog-
ical oscillators in all organisms (22–24). In the course of daily
light-dark cycles, the activity of AANAT and the level of the
23-kDa AANAT protein in the brain’s pineal gland are high
during nocturnal periods and rapidly decrease following expo-
sure to light (1, 20, 25).
In mammals, changes of AANAT levels in the brain’s pineal
gland are controlled by the circadian oscillator in the suprachi-
asmatic nucleus of the hypothalamus. At night, axons of rodent
superior cervical ganglion neurons release norepinephrine in
the pineal gland, in response to circadian signals from the
suprachiasmatic nucleus, thereby activating adrenergic recep-
tors to increase intracellular Ca2 and cAMP. The resulting
phosphorylation of CREB, the cAMP-response element-bind-
ing protein, up-regulates the Aanat transcriptional promoter,
which contains cAMP-response element sequence elements (1,
4, 25–27). Increases in cAMP also stimulate the site-specific
phosphorylation of AANAT by PKA, thereby causing the bind-
ing of AANAT to 14-3-3 proteins. These transitions augment
the enzymatic activity of AANATand inhibit its degradation (1,
6, 7, 28). Although AANAT is predominantly expressed in the
pineal gland and the retina, this enzyme is also present in cells
of the gastrointestinal tract and apparently at other sites as well,
including the hippocampus, the olfactory bulb, the cerebellum,
and the spinal cord (12, 29, 30).
Melatonin is produced from NAS by hydroxyindole-O-
methyltransferase. The levels of NAS, synthesized by AANAT,
can constrain the rate of melatonin synthesis fromNAS during
light parts of daily cycles (when NAS levels are low) but appear
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not to be the rate-limiting step during dark parts of these cycles,
when both AANAT and NAS levels are high (21). In rodents
such as rats, the activity of AANAT starts to increase 3–4 h
after the onset of darkness and begins to decrease before the
onset of light in the morning (21, 31). Hence the importance
of regulating the expression and the enzymatic activity of
AANAT, because these parameters determine the levels of both
NAS and melatonin.
The concentration of AANAT, a largely cytosolic enzyme
(32), is controlled through both transcriptional and post-trans-
lational mechanisms (1, 11, 31, 33–35). In rodents, the onset of
darkness leads to an increase in melatonin (requiring a preced-
ing increase of NAS) after a lag period, whereas in sheep and
primates, increases in melatonin occur rapidly upon the onset
of darkness. The levels of Aanat mRNA in rodents can vary
by 100-fold during light-dark cycles (10), whereas in non-
rodent mammals such as, for example, sheep, these differences
can be as low as 2-fold, suggesting a major involvement of
translational and/or post-translational AANAT regulation in
latter cases (11, 36). In addition to variability in regulation at the
level of AANAT-encoding mRNAs, AANAT is also unusual in
the extent of variability of its N-terminal sequences during ver-
tebrate evolution (Fig. 1C). In 2010, one of our laboratories
showed that N-terminal residues of rat AANAT play a role in
the control of its degradation, suggesting the involvement of the
N-end rule pathway (37).
The N-end rule pathway is a set of intracellular proteolytic
systems whose unifying feature is the ability to recognize and
polyubiquitylate proteins containing N-terminal degradation
signals (degrons) called N-degrons, thereby causing degrada-
tion of these proteins by the proteasome (Fig. 1, A and B) (38–
46). Ubiquitin (Ub) ligases of the N-end rule pathway, called
N-recognins, can recognize not only N-degrons but also spe-
cific internal degradation signals (47–50). The main determi-
nant of an N-degron is either an unmodified or chemically
modified destabilizingN-terminal residue of a protein.Another
determinant of an N-degron is a protein’s internal Lys resi-
due(s). It functions as the site of polyubiquitylation and tends to
be located in a conformationally disordered region (41, 51, 52).
Bacteria also contain the N-end rule pathway, but Ub-indepen-
dent versions of it (53–58).
Regulated degradation of proteins and their natural frag-
ments by the N-end rule pathway has been shown to mediate a
strikingly broad range of biological functions, including the
sensing of heme, nitric oxide (NO), oxygen, and short peptides;
the control of the input stoichiometries of subunits in oligomeric
protein complexes; the elimination of misfolded or otherwise
abnormal proteins; the degradation of specific proteins after
their retrotranslocation to the cytosol from membrane-en-
closed compartments; the regulation of apoptosis and repres-
sion of neurodegeneration; the regulation of DNA repair, tran-
scription, replication, and chromosome cohesion/segregation;
the regulation of G proteins and cytoskeletal proteins, such as
actin and myosin; the regulation of autophagy, peptide import,
meiosis, immunity, fat metabolism, cell migration, cardiovas-
cular development, spermatogenesis, and neurogenesis; the
functioning of adult organs, including the brain, muscle, testis,
and pancreas; and the regulation of leaf and shoot development,
leaf senescence, and many other processes in plants (Fig. 1, A
and B) (see Refs. 41–46 and references therein).
In eukaryotes, the N-end rule pathway consists of two
branches. One branch, called the Ac/N-end rule pathway, tar-
gets proteins for degradation through their N-terminally
acetylated (Nt-acetylated) residues (Fig. 1B) (39, 40, 46, 59–62).
Degradation signals and E3 Ub ligases of the Ac/N-end rule
pathway are called Ac/N-degrons and Ac/N-recognins, respec-
tively. Nt-acetylation of cellular proteins is apparently irre-
versible, in contrast to acetylation-deacetylation of proteins’
internal Lys residues. About 90% of human proteins are
cotranslationally Nt-acetylated by ribosome-associated Nt-
acetylases (63). Ac/N-degrons are present in many, possibly
most, Nt-acetylated proteins (Fig. 1B). Natural Ac/N-degrons
are regulated through their reversible shielding in cognate pro-
tein complexes (59).
The pathway’s other branch, called the Arg/N-end rule path-
way, targets specific unacetylated N-terminal residues (Fig. 1A)
(40, 64–68). The “primary” destabilizing N-terminal residues
Arg, Lys, His, Leu, Phe, Tyr, Trp, and Ile are directly recognized
by N-recognins. The unacetylated N-terminal Met, if it is fol-
lowed by a bulky hydrophobic () residue, also acts as a primary
destabilizing residue (Fig. 1A) (40). In contrast, the unacety-
lated N-terminal Asn, Gln, Asp, and Glu (as well as Cys, under
some metabolic conditions) are destabilizing due to their pre-
liminary enzymatic modifications, which include N-terminal
arginylation (Fig. 1A) (41–43, 69). In the yeast Saccharomyces
cerevisiae, the Arg/N-end rule pathway ismediated by theUbr1
N-recognin, a 225-kDa RING-type E3 Ub ligase and a part of
the targeting complex comprising the Ubr1-Rad6 and Ufd4-
Ubc4/5 E2-E3 holoenzymes (41, 70). In multicellular
eukaryotes, several E3 Ub ligases, including Ubr1, function as
N-recognins of the Arg/N-end rule pathway (Fig. 1A).
In S. cerevisiae, theAc/N-end rule pathway ismediated by (at
least) the cytosolic/nuclear E3 Ub ligase Not4 and by Doa10, an
endoplasmic reticulummembrane-embeddedE3 (59). Inmam-
malian cells, this pathway is mediated by (at least) the Teb4 E3,
which is sequelogous (similar in sequence (71)) to yeast Doa10
(60). HumanRGS2, a regulator of specific G proteins, is a short-
lived substrate of the Ac/N-end rule pathway both in mamma-
lian cells and in the heterologous setting of S. cerevisiae (60, 72,
73). In addition, the naturally occurring (blood pressure-elevat-
ing) human RGS2Q2L mutant (in which Gln at position 2 is
replaced by Leu) is targeted for degradation by both the Ac/N-
end rule pathway and the Arg/N-end rule pathway (60). The
Ac/N-end rule pathway recognizes the Nt-acetylated
Ac-RGS2Q2L (specifically its N-terminal Ac-Met residue),
whereas the non-Nt-acetylated RGS2Q2L is targeted (through
its N-terminalMet-Leu sequence) by the Arg/N-end rule path-
way (60).
In the present work, we analyzed the proteasome-mediated
degradation of rat AANAT (37), whose N-terminal sequence
Met-Leu (Fig. 1C) is identical to that of the otherwise unrelated
human RGS2Q2L protein (60). We also characterized human
AANAT, which is highly sequelogous (71) (84% identical) to rat
AANAT but bears a different N-terminal sequence (Fig. 1C).
Our analyses employed the previously helpful approach of dis-
secting degradation of amammalian protein of interest not only
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in a homologous (mammalian) setting but also in S. cerevisiae
(60, 66), thereby making possible the use of yeast genetics.
We show here that two alternative versions of rat AANAT,
its Nt-acetylated and non-Nt-acetylated forms, are targeted for
degradation by the Ac/N-end rule pathway and the Arg/N-end
rule pathway, respectively. In contrast, human AANAT, whose
N-terminal sequence differs from that of rodent AANATs, is
significantly longer-lived than its rat counterpart and appears
to be largely refractory to degradation by the N-end rule path-
way. Together, these and related results indicate both a major
involvement of the N-end rule pathway in the control of rodent
AANATs and substantial differences in the regulation of rodent
and humanAANATs that stem from differences in their N-ter-
minal sequences.
Results
Wild-type Rat and Human AANATs and Their Mutants—
The start (AUG) codon-encoded N-terminal Met residue of
nascent proteins is cotranslationally cleaved off by ribosome-
associated Met-aminopeptidases (MetAPs) if a residue at posi-
tion 2, to bemadeN-terminal by the cleavage, is not larger than
Val (41, 74). Thus, for example, the Met residue of the N-
terminal Met-Leu-Ser sequence of wild-type rat AANAT
(denoted as MLSrAANAT) (Fig. 1C) is retained in mature
MLSrAANAT, inasmuch as Leu is larger than Val. Given the
previously demonstrated usefulness of employing genetic trac-
tability of S. cerevisiae for understanding the targeting of mam-
malian N-end rule substrates (60, 66), we carried out the pres-
ent study by expressing AANAT test proteins not only in
human HEK293T cells but also in S. cerevisiae. Cited below are
the examined wild-type and mutant AANAT proteins.
When present, parentheses around a superscript’s N-termi-
nal Met residue in the notations of AANAT test proteins
denote the fact that this Met is cotranslationally cleaved off by
MetAPs.
(i) MLSrAANAT3f, the wild-type rat MLSrAANAT C-termi-
nally tagged with a triple-FLAG epitope (Figs. 1C and 2A).
(ii) (M)SMLSrAANAT3f, in which the sequence (Met)-Ser was
placed before the wild-type Met-Leu-Ser sequence of rat
MLSrAANAT3f, yielding the N-terminal sequence (Met)-Ser-
Met-Leu-Ser. Its N-terminal Met residue would be cotransla-
tionally cleaved off by MetAPs (Fig. 2A). The (Met)-Ser
sequence was added to wild-type MLSrAANAT3f in order to
mimic the (Met)-Ser N-terminal sequence of primate (includ-
ing human) AANATs (Fig. 1C).
(iii) (M)SIrAANAT3f, in which Leu at position 2 of the wild-
type rat MLSrAANAT3f (Fig. 1C) was deleted, thereby making
the N-terminal Met of the resulting (M)SIrAANAT3f removable
by MetAPs (Figs. 1C and 2A).
(iv) (M)PLSrAANAT3f, in which the Pro residue was inserted
between N-terminal Met and second-position Leu of wild-type
rat MLSrAANAT3f. This alteration aimed to address the rele-
vance of Nt-acetylation to the degradation of wild-type rat
MLSrAANAT3f. Specifically, the N-terminal sequence Met-
Leu-Ser is a priori likely to be cotranslationally Nt-acetylated in
vivo at its (retained) N-terminal Met (59, 62, 63). In contrast,
theN-terminalMet residue of themutantN-terminal sequence
(Met)-Pro-Leu-Ser of (M)PLSrAANAT3f would be cotransla-
tionally cleaved off byMetAPs. The resulting N-terminal Pro is
not Nt-acetylated, at least in S. cerevisiae, and is usually not
Nt-acetylated in mammalian cells as well (59, 63).
(v) MLSrAANAT3ha, the wild-type rat MLSrAANAT (Fig. 1C)
C-terminally tagged with a triple-HA epitope. It was used as a
control for the MLSrAANAT3haK8R mutant described in item viii.
(vi) (M)SThAANAT3f, the wild-type human (M)SThAANAT
(Fig. 1C) C-terminally tagged with a triple-FLAG epitope.
(vii) (M)PThAANAT3f, in which the second-position Ser of
thewild-type human (M)SThAANAT3f (Fig. 1C) was replaced by
the Pro residue, yielding (M)PThAANAT3f. TheN-terminalMet
residue of either the wild-type human (M)SThAANAT3f or the
mutant (M)PThAANAT3f would be cotranslationally removed
byMetAPs (41, 74).However, in contrast to the resultingN-ter-
minal Ser of wild-type SThAANAT3f, which would be expected
to be cotranslationally Nt-acetylated, the N-terminal Pro of the
mutant PThAANAT3f is not Nt-acetylated, at least in S. cerevi-
siae, and is usually notNt-acetylated inmammalian cells as well
(59, 63).
(viii) MLSrAANAT3haK8R, the otherwise wild-type triple-HA-
tagged rat MLSrAANAT in which the Lys-8 residue was
replaced by Arg.
(ix) MLSrAANAT3haKzero, the otherwise wild-type triple-HA-
tagged rat MLSrAANAT in which each of its four Lys residues
were replaced by Arg (Fig. 6B).
(x) (M)SThAANAT3haKzero, the otherwise wild-type triple-HA-
tagged human (M)SThAANAT in which both of its Lys residues
were replaced by Arg (Fig. 7, A and D).
Degradation of Rat AANAT by the S. cerevisiae N-end Rule
Pathway—In cycloheximide (CHX) assays, a protein of interest
is analyzed by immunoblotting as a function of time after the
inhibition of translation byCHX (39, 59, 60). Both thewild-type
rat MLSrAANAT3f (Fig. 1C) and its (M)SMLSrAANAT3f mutant
(see item ii above) were rapidly degraded in wild-type S. cerevi-
siae, with half-lives (t1⁄2) 5 min (Fig. 2, B (lanes 3–10) and D).
In striking contrast, (M)SIrAANAT3f (see item iii above), pro-
duced from wild-type MLSrAANAT3f by deleting the Leu resi-
due at position 2, was virtually completely stable under the
same conditions, with a t1⁄2 1 h (Fig. 2, B (lanes 11–14) andD).
Because the N-terminal Met residue in the Met-Leu-Ser
sequence of the wild-type rat MLSrAANAT3f would be likely to
be Nt-acetylated in vivo (59, 62, 63), the rapid degradation of
MLSrAANAT3f (t1⁄2  5 min) (Fig. 2, B and D) suggested the
involvement of the Ac/N-end rule pathway (Fig. 1A). To
address this possibility, we constructed the non-Nt-acetylat-
able (M)PLSrAANAT3f mutant (see item iv above). (This mutant
would also not be expected to be targetable by the Arg/N-end
rule pathway, because the latter does not recognize N-terminal
Pro (40, 41).) Remarkably, (M)PLSrAANAT3f was long-lived in
S. cerevisiae, in comparison with the short-lived wild-type
MLSrAANAT3f (t1⁄2  1 h versus t1⁄2  5 min, respectively),
strongly suggesting (but not proving) a role for the Ac/N-end
rule pathway in the degradation of the wild-type rat
MLSrAANAT3f (Fig. 2, B (lanes 15–18) and D; also see below).
To further address the involvement of theAc/N-end rule and
Arg/N-end rule pathways (Fig. 1,A and B) in the degradation of
wild-type MLSrAANAT3f, we performed CHX-chases in
S. cerevisiaemutants that lacked essential components of either
Degradation of AANAT by the N-end Rule Pathway
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one or both of these pathways. The normally short-lived rat
MLSrAANAT3f (t1⁄2  5 min; Fig. 2, C (lanes 2–5) and E) was
partially stabilized in bothnaa30 andubr1mutants (Fig. 2,C
(lanes 6–9 and 14–17) and E). S. cerevisiae naa30 cells lack
the cognate NatC Nt-acetylase whose substrates include pro-
teins bearing the N-terminal Met-Leu sequence (59, 62, 63, 75,
76). S. cerevisiae ubr1 cells lack Ubr1, the E3 Ub ligase
(N-recognin) that is essential for the proteolytic activity of the
Arg/N-end rule pathway (Fig. 1A) (40, 41, 59).
Crucially, the relative stabilization ofMLSrAANAT3fwas dra-
matically higher in the double mutant naa30 ubr1 than in
either one of the single mutants (Fig. 2, C (lanes 18–21) and E).
These findings should be considered together with the concep-
tually independent result that the non-Nt-acetylatable (and
FIGURE 1. The mammalian N-end rule pathway and N-terminal regions of AANAT enzymes. See the Introduction for references and descriptions of the
pathway’s mechanisms and biological functions. Amino acid residues are denoted by single-letter codes. A, themammalian Arg/N-end rule pathway. It targets
proteins for degradation through their specific unacetylated N-terminal residues. A yellow oval denotes the rest of a protein substrate. Primary, secondary, and
tertiary, mechanistically distinct classes of destabilizing N-terminal residues. Ntan1 and Ntaq1, N-terminal amidases (Nt-amidases) that convert the tertiary
destabilizing N-terminal residues Asn and Gln to Asp and Glu, respectively. The Ate1 arginyltransferase (R-transferase) conjugates Arg, a primary destabilizing
residue, to N-terminal Asp, Glu, and (oxidized) Cys. Type 1 and type 2, two sets of primary destabilizing N-terminal residues, basic (Arg, Lys, and His) and bulky
hydrophobic (Leu, Phe, Trp, Tyr, Ile, and Met, if the latter is followed by a bulky hydrophobic residue ()), respectively. These sets of N-terminal residues are
recognized by two distinct substrate-binding sites of N-recognins, the pathway’s E3 ubiquitin ligases, whose (possibly incomplete) list includes Ubr1, Ubr2,
Ubr4, andUbr5. B, mammalian Ac/N-end rule pathway. It targets proteins through their N-terminally acetylated (Nt-acetylated) residues. Red arrowon the left,
cotranslational removal of the N-terminal Met residue byMet-aminopeptidases (MetAPs). N-terminal Met is retained if a residue at position 2 is larger than Val.
C, the first 10 amino acid residues of animal AANAT enzymes, in vertebrates and an invertebrate, such as Drosophila melanogaster. See the Introduction for
descriptions of AANATs.
Degradation of AANAT by the N-end Rule Pathway
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also not targetable by the Arg/N-end rule pathway)
(M)PLSrAANAT3f mutant (see the preceding paragraph) was
much longer-lived in wild-type S. cerevisiae than its wild-type
MLSrAANAT3f counterpart (Fig. 2, B (lanes 15–18 versus lanes
3–6) andD). Together, these sets of findings indicated that the
wild-type rat MLSrAANAT3f (its two alternative forms) was tar-
geted for degradation by both the Ac/N-end rule pathway and
the Arg/N-end rule pathway. Specifically, the Nt-acetylated
Ac-MLSrAANAT3f is destroyed through the recognition of
its Nt-acetylated N-terminal Met residue by the Ac/N-end
rule pathway (Fig. 1B), whereas the non-Nt-acetylated
MLSrAANAT3f is targeted by the “complementary” Arg/N-end
rule pathway, which recognizes the unacetylated N-terminal
Met-Leu sequence of MLSrAANAT3f as the Met- motif
(N-terminal Met followed by a bulky hydrophobic residue)
(Fig. 1A).
This conclusion was in agreement with the finding that the
rapid degradation of MLSrAANAT3f in wild-type S. cerevisiae
FIGURE 2. The wild-type rat MLSrAANAT as a substrate of both branches of the N-end rule pathway. A, the wild-type rat MLSrAANAT and its mutants that
were constructed and analyzed in the present study. Amino acid residues are denoted by single-letter codes. The Leu residue, at position 2 in wild-type
MLSrAANAT, is highlighted in red to make it easier to follow sequence alterations in specific mutants. B, immunoblotting with antibody to actin was used as a
loading control. Lane 1, fluorescently labeledmolecularmassmarkers (LI-COR); theirmasses, in kDa, are indicatedon the left. Lane 2, wild-type S. cerevisiaewere
transformed with vector (V) alone (control). CHX-chases were performed at 30 °C for the indicated times in wild-type S. cerevisiae with the wild-type rat
MLSrAANAT3f (lanes 3–6) andwith itsmutants
(M)SMLSrAANAT3f (lanes 7–10),
(M)SIrAANAT3f (lanes 11–14), and
(M)PLSrAANAT3f (lanes 15–18). The bands of AANAT3f
and actin are indicated on the right. C, immunoblotting with antibody to tubulin was used as a loading control. Lane 1, 37 and 50 kDamolecular massmarkers
(see lane 1 in B). Shown are CHX-chases with the wild-type rat MLSrAANAT3f in wild-type S. cerevisiae (lanes 2–5) and its mutants naa30 (lanes 6–9), naa10
(lanes 10–13), ubr1 (lanes 14–17), naa30 ubr1 (lanes 18–21), and naa10 ubr1 (lanes 22–25). The bands of MLSrAANAT3f and tubulin are indicated on the
left.D, quantification of data in B. E, quantification of data in C. All quantified CHX-chase assays were carried out at least three times and yielded results within
10% of the data shown.
Degradation of AANAT by the N-end Rule Pathway
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(t1⁄2  5 min) remained unchanged in naa10 cells, which
lacked the non-cognate NatANt-acetylase (which does not Nt-
acetylate N-terminal Met) (59, 76). Furthermore and also in
agreement with the above conclusion, the degradation of
MLSrAANAT3f in double-mutant naa10 ubr1 cells pro-
ceeded at a rate similar to that in the single ubr1 mutant
(Fig. 2, C (lanes 22–25) and E). Thus, a double-mutant back-
ground that nearly completely stabilizes the wild-type rat
MLSrAANAT3f must be naa30 ubr1 in that it should also
lack the activity of the cognate NatC Nt-acetylase (Fig. 2, C
(lanes 18–21) and E). In agreement with this conclusion, the
ablation of NAA10, encoding the non-cognate NatA Nt-acety-
lase, did not have a synergistic effect on the rate of
MLSrAANAT3f degradation in double-mutant naa10 ubr1
cells (Fig. 2, C (lanes 22–25) and E).
Previous work has identified the endoplasmic reticulum
membrane-embedded E3 Ub ligase Doa10 as one Ac/N-
recognin of the S. cerevisiae Ac/N-end rule pathway (39, 59).
We found that the degradation of the wild-type rat
MLSrAANAT3f (t1⁄2 5min in wild-type S. cerevisiae) was not
significantly impaired in doa10 cells, in comparison with
wild-type cells (Fig. 3, D and F). We did not examine, so far,
the other yeast Ac/N-recognin, Not4 (see the Introduction)
for its possible role in targeting the Nt-acetylated rat
Ac-MLSrAANAT3f in S. cerevisiae. We also do not know, thus
far, whether Teb4, the mammalian counterpart of the yeast
Doa10 Ac/N-recognin (60), is involved in the degradation of
rat MLSrAANAT3f in a homologous (mammalian) setting.
Degradation of Rat AANAT Is Proteasome-dependent and
DoesNot Require Lys-8—Thedemonstrated degradation of two
forms of the wild-type rat MLSrAANAT3f (Ac-MLSrAANAT3f
and its non-Nt-acetylated counterpart) by the two branches of
theN-end rule pathway (Fig. 2) already implied the proteasome
dependence of this degradation, given the known organization
of the N-end rule pathway (Fig. 1, A and B). To verify this in
S. cerevisiae by independent means, CHX-chases with rat
MLSrAANAT3f were carried out in wild-type versus pdr5 cells
in either the presence or absence of the MG132 proteasome
inhibitor. (Cells lacking the transmembrane transporter PDR5
are more sensitive to MG132 (77, 78).)
As expected, given the proteasome dependence of the N-end
rule pathway (Fig. 1, A and B), the normally rapid degradation
of the wild-type rat MLSrAANAT3f was substantially inhibited
inwild-type S. cerevisiae in the presence of 50MMG132 (Fig.
4, A and B). This degradation was inhibited even more
strongly in mutant pdr5 cells under the same conditions,
confirming the proteasome dependence of at least the bulk
of MLSrAANAT3f degradation (Fig. 4, A and B).
N-terminal regions ofmammalianAANATs contain a highly
conserved Lys residue (e.g. Lys-8 in rat AANAT and Lys-10 in
human AANAT) that has been suggested as a potential ubiqui-
tylation site and thus a determinant of the AANAT degron (33,
79–81). To address this possibility, CHX-chases were per-
formed in S. cerevisiae with wild-type MLSrAANAT3ha and a
mutant containing a Lys-83Arg mutation (MLSrAANAT3haK8R).
Wild-type MLSrAANAT3ha and the mutant MLSrAANAT3haK8R
were degraded at similar rates, indicating that the conserved
lysine at this position (Lys-8 in ratMLSrAANAT) is not, by itself,
a significant determinant of MLSrAANAT stability (Fig. 4C).
Degradation of Human AANAT in S. cerevisiae—Fig. 3 (A
(lanes 6–9) and B) shows the results of a CHX-chase, in wild-
type yeast, with the 207-position residue (not counting the tag)
(M)SThAANAT3f, the wild-type human AANAT C-terminally
tagged with a triple-FLAG epitope. Parentheses around the
superscript’s N-terminal Met residue denote the fact that this
Met is cotranslationally cleaved off by MetAPs. Whereas
human (M)SThAANAT3f was relatively unstable in S. cerevisiae
(t1⁄2  30 min), it was much longer-lived (including its higher
zero-time, prechase level) than thewild-type rat MLSrAANAT3f
under the same conditions (Fig. 3, A and B).
As was also done with the wild-type rat MLSrAANAT3f (Fig.
2C), we characterized the degradation of wild-type human
(M)SThAANAT3f in S. cerevisiae strains deficient in specific
components of the N-end rule pathway. The N-terminal Ser-
Thr sequence of wild-type human (M)SThAANAT3f (after the
cotranslational removal of the initially presentN-terminalMet)
made it likely that (M)SThAANAT3f was cotranslationally Nt-
acetylated in vivo (59, 63). This modification of human
(M)SThAANAT3f would make it a potential target for degrada-
tion by the Ac/N-end rule pathway (Fig. 1B). In contrast, the
non-Nt-acetylated human (M)SThAANAT3f would not be
expected to be recognized by either the Ac/N-end rule or the
Arg/N-end rule pathway (Fig. 1A), in the latter case due to
the absence of both a destabilizing N-terminal residue and a
bulky hydrophobic () second residue. (A Met- N-termi-
nal motif, containing a second-position residue, can act as
an N-degron recognized by the Arg/N-end rule pathway
(60, 82).
Indeed, the rate of degradation of human (M)SThAANAT3f in
ubr1 S. cerevisiae, which lacked the Ubr1 N-recognin and
therefore lacked the Arg/N-end rule pathway (Fig. 1A), was
similar to the rate of (M)SThAANAT3f degradation in wild-type
cells (Fig. 3,C (lanes 1–4 versus lanes 9–12),D (lanes 2–5 versus
lanes 14–17), E, and F). The rate of (M)SThAANAT3f degrada-
tion that was observed with wild-type S. cerevisiae was also not
significantly changed in doa10 cells, which lacked one of two
knownAc/N-recognins of the Ac/N-end rule pathway (Figs. 1B
and 3, D (lanes 10–13 versus lanes 2–5) and F). Surprisingly,
however, (M)SThAANAT3f was strongly destabilized in naa10
cells, which lacked the cognate Nt-acetylase for the N-terminal
Ser residue (59, 62); similar results were obtained with double-
mutant naa10 ubr1 cells (Fig. 3, C–F).
Given themuch faster degradation of (M)SThAANAT3f in the
absence of Naa10 (e.g. Fig. 3,C (lanes 1–4 versus lanes 5–8) and
E) (i.e. in cells that would be incapable of Nt-acetylating
(M)SThAANAT3f), we also carried out CHX-chases, in wild-
type S. cerevisiae, with (M)PThAANAT3f. In the latter mutant,
the N-terminal Ser was replaced by the non-Nt-acetylatable
Pro residue. In contrast to wild-type (M)SThAANAT3f
in naa10 cells, in which the (non-Nt-acetylated)
(M)SThAANAT became strikingly short-lived, the (non-Nt-
acetylatable) (M)PThAANAT mutant was found to be longer-
lived, in wild-type cells, than the Nt-acetylatable wild-type
(M)SThAANAT3f (Fig. 4, D and E). These results indicated that
the observed accelerated degradation of the wild-type human
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(M)SThAANAT in naa10 S. cerevisiae was not caused by the
failure to Nt-acetylate (M)SThAANAT in the absence of the
NatA Nt-acetylase.
We do not understand the mechanistic cause of the (repro-
ducibly observed) much faster degradation of human
(M)SThAANAT in naa10 S. cerevisiae (Fig. 3, C–F). One pos-
sibility, which remains to be examined, is the apparent inhibi-
tion of the yeast Hsp90 chaperone system (centered on the
S. cerevisiaeHsc82/Hsp82 proteins) in naa10 cells.3 If human
(M)SThAANAT expressed in wild-type S. cerevisiae is a pro-
tected (from degradation) client of the Hsc82/Hsp82 system, a
failure of this protection in naa10 mutant cells would make
(M)SThAANAT vulnerable to a currently unknown pathway of
3 J.-H. Oh and A. Varshavsky, unpublished data.
FIGURE 3. Degradation assays with the wild-type human (M)SThAANAT in S. cerevisiae. A, comparison of degradation rates of the wild-type rat
MLSrAANAT3f and the wild-type human
(M)SThAANAT3f in S. cerevisiae. Immunoblotting with antibody to actin was used as a loading control. Lane 1,
wild-type S. cerevisiae were transformed with vector (V) alone (control). CHX-chases were performed at 30 °C for the indicated times in wild-type
S. cerevisiae with the wild-type rat MLSrAANAT3f (lanes 2–5) and with the wild-type human
(M)SThAANAT3f (lanes 6–9). The bands of AANAT and actin are
indicated on the left. B, quantification of data in A. C, CHX-chases with the wild-type human (M)SThAANAT3f in wild-type S. cerevisiae (lanes 1–4) and its
mutants naa10 (lanes 5–8), ubr1 (lanes 9–12), and naa10 ubr1 (lanes 13–16). The bands of human (M)SThAANAT3f and actin are indicated on the left.
D, lane 1, wild-type S. cerevisiae were transformed with vector (V) alone (control). Shown are CHX-chases with the wild-type human (M)SThAANAT3f in
wild-type S. cerevisiae (lanes 2–5) and its mutants naa10 (lanes 6–9), doa10 (lanes 10–13), and ubr1 (lanes 14–17). The bands of human
(M)SThAANAT3f and actin are indicated on the left. E, quantification of data in C. F, quantification of data inD. All quantified CHX-chase assays were carried
out at least three times and yielded results within 10% of the data shown.
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theUb system that is distinct from theArg/N-end rule pathway.
(A proteolytic pathway in question would be distinct from the
Arg/N-end rule pathway because (M)SThAANAT was equally
short-lived in single-mutant naa10 and double-mutant
naa10 ubr1 cells (Fig. 3, C–F).) In sum, the above Hsp90-
based mechanism (which remains to be addressed in the
context of the (M)SThAANAT protein) might underlie the
strongly accelerated degradation of (M)SThAANAT in naa10
S. cerevisiae.
Degradation of Rat AANAT in Human HEK293T Cells—To
compare the relative rates of degradation of N-terminal
mutants of rat AANAT in humanHEK293T cells, the wild-type
rat MLSrAANAT3f and its mutants (M)SMLSrAANAT3f,
(M)SIrAANAT3f, and (M)PLSrAANAT3f (see items i–iv at the
beginning of “Results”) were expressed in these cells using tran-
sient transfection. Preliminary experiments with wild-type
MLSrAANAT3f encoded by a pcDNA3-based plasmid and
expressed from the full-strength PCMV promoter indicated that
the levels of expression of MLSrAANAT3f were high enough
to saturate or nearly saturate pathways that targeted
MLSrAANAT3f for degradation in HEK293T cells. Specifically,
at those (high) levels of expression, wild-type rat MLSrAANAT3f
either was stable or was degraded slowly (data not shown).
We addressed this problem by constructing a set of trun-
cated derivatives of the original PCMV promoter, aiming to
attenuate its activity. The resulting nested set of truncated
promoters, denoted as PCMVt1, PCMVt2, and PCMVt3, com-
prised progressively shortened versions of the original PCMV.
These truncations (Fig. 5A) were similar (although not iden-
tical) to a series of PCMV truncations described earlier by
FIGURE 4. Degradation assays with a proteasome inhibitor and AANATmutants in S. cerevisiae. A, lane 1, wild-type S. cerevisiae were transformed with
vector (V) alone (control). Lanes 2–5, CHX-chase was performed at 30 °C for the indicated times in wild-type S. cerevisiaewith the wild-type rat MLSrAANAT3ha.
Lanes 6–9, sameas in lanes 2–5, but theCHX-chasewas in thepresenceof theMG132proteasome inhibitor (see “Experimental Procedures”). Lanes 10–13, same
as in lanes 2–5but inpdr5 S. cerevisiae lacking the efflux pumpPdr5. Lanes 14–17, sameas in lanes 10–13but in thepresenceofMG132. Thebands of actin and
MLSrAANAT3ha are indicated on the left. B, quantification of data in A. C, CHX-chases were performed in wild-type S. cerevisiae with the wild-type rat
MLSrAANAT3ha (lanes 2–5) and with its Lys-83 Argmutant
MLSrAANAT3ha
K8R (see “Results”). The bands of tubulin and AANAT are indicated on the left. An asterisk
on the right denotes a band of protein that cross-reactedwith anti-HA antibody (the band is also present in lane 1, the vector-only control).D, lane 1, wild-type
S. cerevisiaewere transformedwith vector (V) alone (control). Lanes 2–5, CHX-chasewasperformedat 30 °C for the indicated times inwild-type S. cerevisiaewith
the wild-type human (M)SThAANAT3f. Lanes 6–9, same as in lanes 2–5 but with the mutant human
(M)PThAANAT3f. The bands of actin and AANAT are indicated
on the left. E, quantification of data inA. All quantified CHX-chase assayswere carried out at least three times and yielded results within 10%of the data shown.
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Promega Inc. (83). Each of the PCMVt1, PCMVt2, and PCMVt3
promoter variants was cloned into pcDNA3, replacing full-
length PCMV.
The wild-type rat MLSrAANAT3f was cloned into each of the
above pcDNA3-based plasmids, and CHX-chases were per-
formed in HEK293T cells transiently transfected with these
constructs. Expression of MLSrAANAT3f from the PCMVt1 and
PCMVt2 promoters reduced time-zero levels of MLSrAANAT3f
(measured by immunoblotting at the beginning of CHX-chase)
by 70% and by 97%, respectively, in comparison with the
unmodified PCMV promoter (Fig. 5, A–C). With the most trun-
cated promoter, PCMVt3, noMLSrAANAT3f could be detected at
the same level of immunoblotting sensitivity (data not shown).
The lower levels of MLSrAANAT3f expression that have been
attained through the use of the PCMVt1 and PCMVt2 promoters
resulted in a strongly increased rate of the post-translational
degradation of MLSrAANAT3f (t1⁄2  2 h versus t1⁄2  8 h when
MLSrAANAT3f was expressed from the full-length PCMV pro-
moter; Fig. 5, A–C). Treatment of HEK293T cells with the pro-
teasome inhibitorMG132 during the chase increased the levels
of MLSrAANAT3f expressed from these promoters, thereby
confirming that in each case, the bulk of degradation was
proteasome-dependent (Fig. 5, A–C). The pcDNA3CMVt1 plas-
mid, which contained PCMVt1, one weakened version of the
PCMV promoter, was chosen for experiments with HEK293T
cells in this study.
In agreement with the relative metabolic stabilities of
AANATproteins expressed in S. cerevisiae (Fig. 1,A andB), the
mutant rat (M)SIrAANAT3f, bearing a deletion of the Leu resi-
due at position 2 of wild-type MLSrAANAT3f (Fig. 2A), was the
longest-lived protein in the set of rat AANAT mutants exam-
ined in HEK293T cells (t1⁄2 4 h; Fig. 6,A (lanes 12–16) andC).
The wild-type rat MLSrAANAT3f and its (M)SMLSrAANAT3f
mutant (see items i and ii at the beginning of “Results”) were
significantly shorter-lived inHEK293T cells than (M)SIrAANAT3f,
with t1⁄2 1 h and t1⁄2 1 h, respectively, versus t1⁄2 4 h (Fig. 6,
A (lanes 2–11) and C).
We expected, a priori, that (M)SMLSrAANAT3f would initiate
from the first encoded Met residue, particularly because of the
inclusion of the Kozak “optimal” upstream sequence in the rel-
evant plasmids used for expression of test AANAT proteins.
We could verify that expectation through chase-degradation
assays using an affinity-purified antibody against the Nt-acety-
lated N terminus of MLSrAANAT3f (Fig. 5D). We produced
and purified this antibody as described under “Experimental
Procedures.” As shown in Fig. 5D, immunoblotting of SDS-
PAGE-fractionated samples containing MLSrAANAT3f or
(M)SMLSrAANAT3f with the anti-Ac- MLSrAANAT antibody
generated a positive signal only in samples expressing
MLSrAANAT3f. If a construct expressing (M)SMLSrAANAT3f
had initiated translation (to a significant extent) from the sec-
ond Met residue, the resulting translated protein would have
been MLSrAANAT3f. However, no signal was detected (using
the above anti-Ac-MLSrAANAT antibody) with samples con-
taining (M)SMLSrAANAT3f (Fig. 5D), indicating negligible levels
of translation initiation at the position 2 Met.
Although the mutant (M)PLSrAANAT3f was partially stabi-
lized relative to wild-type MLSrAANAT3f, the former protein
FIGURE 5.Weakened derivatives of the PCMVpromoter in HEK293T cells
anddegradation assays using antibody toNt-acetylated rat MLSrAANAT.
A, a simplified diagram of the “wild-type” (unmodified) PCMV promoter in the
cloning vector, with schematically illustrated binding sites for the NFB, SP1,
andCREB transcriptional regulators. Two 5	-terminal truncations ofwild-type
PCMV, denoted as PCMVt1 and PCMVt2, are also indicated. B, lane 1, HEK293T cells
were transformed with vector (V) alone (control). CHX-chases were per-
formed at 37 °C for the indicated times inHEK293T cellswith thewild-type rat
MLSrAANAT3f expressed either from the unmodified PCMV promoter (lanes
2–5), from the PCMVt1 promoter (lanes 7–10), or from the PCMVt2 promoter
(lanes 12–15). Lanes 6, 10, and 16, same as lanes 5, 9, and 15 except that the
MG132proteasome inhibitorwaspresentduring8-hCHX-chases in each case
(see “Experimental Procedures” and “Results”). The bands of tubulin and
MLSrAANAT3f are indicated on the left. C, quantification of data in B. Symbols
shown separately and framed in black squares correspond to altered
(increased) levels of test proteins in the presence of MG132. All quantified
CHX-chase assays were carried out at least three times and yielded results
within 10% of the data shown. D, immunoblotting with affinity-purified anti-
body to Nt-acetylated MLSrAANAT (see “Experimental Procedures”). Lane 1,
HEK293T cells were transformed with vector (V) alone (control) bearing the
(weakened) PCMVt1 promoter. CHX-chases were performed at 30 °C for the
indicated times in HEK293T cells with the wild-type rat MLSrAANAT3f (lanes
2–5) and its mutant (M)SMLSrAANAT3f (lanes 7–10). Lanes 6 and 11, same as
lanes 5 and 10 except that theMG132 proteasome inhibitor was present dur-
ing 4-h CHX-chases in each case (see “Experimental Procedures”). The bands
of rAANAT and tubulin (the latter a loading control) are indicated on the left.
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was still significantly shorter-lived (t1⁄2  2 h) than the most
stable (M)SIrAANAT3f mutant (Fig. 6, A (lanes 17–21) and C).
Although N-terminal Pro is not Nt-acetylated (59, 63) (this
makes N-terminal Pro-bearing proteins invulnerable to the
Ac/N-end rule pathway), theN-terminal Pro residuemight still
be (weakly) recognized by the Arg/N-end rule pathway in some
sequence contexts. Specifically, our SPOT-type, peptide-based
binding assays (84) suggested that the Ubr1 N-recognin of the
FIGURE 6.Degradation and ubiquitylation assays with rat and human AANATs in human HEK293T cells. A, lane 1, HEK293T cells were transformed with
vector (V) alone (control) bearing the (weakened) PCMVt1 promoter (see “Results” and Fig. 5, A–C). Immunoblotting with antibody to tubulin was used as a
loading control. CHX-chases were performed at 37 °C for the indicated times in HEK293T cells with the wild-type rat MLSrAANAT3f (lanes 2–5) and with its
mutants (M)SMLSrAANAT3f (lanes 7–10),
(M)SIrAANAT3f (lanes 12–15), and
(M)PLSrAANAT3f (lanes 17–20). Lanes 6, 11, 16, and 21, sameas lanes 5, 10, 15, and 20 except
that theMG132proteasome inhibitorwas present during a 4-h CHX-chase in each case (see “Experimental Procedures”). The bands of AANAT3f and tubulin are
indicated on the right. An asterisk on the left denotes a band of protein that cross-reacted with anti-FLAG antibody (the band is also present in lane 1, the
vector-only control). B, left, lane 1, same as the control in lane 1 of A. CHX-chases were performed at 37 °C for the indicated times in HEK293T cells with the
wild-type ratMLSrAANAT3ha (lanes 2–5) andwith its lysine-lackingmutant
MLSrAANAT3ha
Kzero (lanes 7–10). Lanes 6 and11, sameas lanes 5 and10except thatMG132
was present during a 4-h CHX-chase in each case. Right, same as in the left panel, but both the wild-type MLSrAANAT3f and its lysine-lacking counterpart were
C-terminally tagged with a triple-FLAG tag, which contains a Lys residue, in contrast to the HA tag, which lacks lysines (see “Results” and “Discussion”). C,
quantification of data in A.D, quantification of data in B. Symbols shown separately and framed in black squares or rectangles correspond to altered levels of test
proteins in the presence of MG132. All quantified CHX-chase assays were carried out at least three times and yielded results within 10% of the data shown. E,
immunoblot analyses (IB), using anti-Ub antibody, of total, input (before immunoprecipitation) extracts from HEK293T cells that had been transfected either
with vector alone (lanes 1 and 2) or with plasmid expressing the wild-type rat MLSrAANAT3ha (lanes 3 and 4) or with plasmid expressing its lysine-lacking
counterpart MLSrAANAT3ha
Kzero (lanes 5 and 6). The MG132 proteasome inhibitor was either omitted (lanes 1, 3, and 5) or added to HEK293T cells (to a final
concentration of 10M) 6 h before preparation of extracts (lanes 2, 4, and 6). The bottom panel shows the results of detecting non-ubiquitylated MLSrAANAT3ha
(absent in the control lanes 1 and 2) with anti-HA antibody. F, same as in E but immunoblot analyses (using anti-Ub antibody) of the input samples after their
immunoprecipitation (IP) with anti-HA antibody (followed by SDS-PAGE) to isolate and detect ubiquitylated AANAT3ha species.
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S. cerevisiae Arg/N-end rule pathway (and, by inference, mam-
malian Ubr1 and Ubr2 as well) may weakly bind to N-terminal
Pro when this residue is followed by a hydrophobic residue.4
Thus, one interpretation of the “residual” instability of the rat
(M)PLSrAANAT3f mutant (in comparison with the longest-lived
(M)SIrAANAT3f mutant) is that the (non-Nt-acetylated) N-ter-
minal sequence Pro-Leu of (M)PLSrAANAT3f is weakly targeted
by the Arg/N-end rule pathway, in contrast to the absence
of targeting of the N-terminal Ser-Ile sequence of the
(M)SIrAANAT3fmutant (Fig. 6,A andC; also see Fig. 2,B andD).
As mentioned above, we found that transient transfection-
based expression of AANAT from the full-strength PCMV pro-
moter could be high enough to result in saturation or near sat-
uration of the relevant proteolytic pathways. Although the use
of the considerably weaker PCMVt1 promoter at least partially
solved this problem (see above), additional studies would be
required tomake sure that pathway saturation effectswere con-
sistently negligible with longer-lived AANAT derivatives that
were expressed from PCMVt1. That said, the preponderance of
our datamakes it nearly certain that the observed differences in
time-zero (before chase) levels ofAANATproteinswere caused
largely by differences in the rates of their degradation.
TheBulk ofDegradation of RatAANAT IsMediated byPolyu-
biquitylation of Its Lys Residue(s)—An earlier study, in which
the wild-type rat MLSrAANATwas apparently not stabilized by
conversion of its Lys residues to Arg, was based on measure-
ments of steady-state levels of MLSrAANAT in HEK293
cells that had been treated or left untreated with the protea-
some inhibitor MG132 (37). To address this issue more di-
rectly, we generated a triple-HA-tagged mutant, denoted
MLSrAANAT3haKzero, of the wild-type rat MLSrAANAT in which
all four of its Lys residues were converted to Arg. (A FLAG-
based epitope tag could not be employed in these experiments,
because FLAG contains a Lys residue that could potentially
serve as a target for polyubiquitylation.)
CHX-chases in HEK293T cells (performed as described above)
with the wild-type MLSrAANAT3ha versus its lysine-lacking
MLSrAANAT3haKzero mutant indicated that MLSrAANAT3haKzero was
nearly completely stable during the chase (t1⁄2 4 h), whereas the
wild-type MLSrAANAT3ha was degraded, with t1⁄2 2 h (Fig. 6, B
andD). A treatmentwithMG132 duringCHX-chase strongly sta-
bilized thewild-typeMLSrAANAT3ha, confirming that itsdegrada-
tion is proteasome-dependent (Fig. 6,B (left, lanes 2 and 6) andD).
In contrast, the MG132 treatment during CHX-chase of the
lysine-lackingMLSrAANAT3haKzeromutant produced atmost amar-
ginal stabilizing effect, suggesting that even if there is a small
(residual) amount of lysine-independent degradation of
MLSrAANAT3haKzero, such a degradation would still require the pro-
teasome (Fig. 6, B (left, lanes 7 and 11) andD).
In a different approach to the same problem, HEK293T cells
were transiently transfectedwith the pcDNA3vector orwith plas-
mids expressing either MLSrAANAT3ha or MLSrAANAT3haKzero.
Cellswere then treated for 6hwith eitherMG132or an equivalent
volume of DMSO (in which the stock solution of MG132
was made). Thereafter, cell extracts were immunoprecipitated
with anti-HA magnetic beads, and the immunoprecipi-
tates were fractionated by SDS-PAGE, followed by immunoblot-
ting with anti-HA and anti-ubiquitin antibodies. Polyubiquitin
chains (apparently linked to MLSrAANAT3ha) could be readily
detected in fractionated immunoprecipitates of extracts fromcells
that expressed MLSrAANAT3ha (but, crucially, not from cells that
expressed an empty vector), and the levels of polyubiquitin chains
were significantly increased in the presence of MG132 (Fig. 6F,
lanes 1–4). In contrast, significantly lower amounts of polyubiqui-
tin chains were observed in fractionated immunoprecipitates
of extracts from cells that expressed the lysine-lacking
MLSrAANAT3haKzero (Fig. 6F, lane 5). Moreover, the presence of
MG132 did not increase the low levels of detected polyubiquitin
chains (Fig. 6F, lane 5 versus lane 6). The latter result suggested
that (residual) polyubiquitin chains observed in cells that
expressedMLSrAANAT3haKzeromay be of a kind (e.g. see Ref. 85) that
do not contribute to the proteasome-dependent degradation of
MLSrAANAT3haKzero. In agreement with this interpretation, the
lysine-lacking MLSrAANAT3haKzero mutant was expressed at signifi-
cantly higher steady-state levels than the wild-type rat
MLSrAANAT3ha in theabsenceofMG132(inDMSO-treatedcells)
(Fig. 6E, bottom), suggesting that the absence of Lys residues sta-
bilized MLSrAANAT3haKzero against degradation throughout life his-
tories of MLSrAANAT3haKzero molecules, including, possibly, their
degradation during or immediately after their synthesis.
Degradation of HumanAANAT inHumanHEK293T Cells—
Degradation of the wild-type human (M)SThAANAT3f and its
N-terminal Pro residue-bearing mutant (M)PThAANAT3f (see
items vi and vii at the beginning of “Results”) were examined by
CHX-chases in HEK293T cells. In agreement with the findings
in S. cerevisiae (Figs. 2 and 3), the wild-type human
(M)SThAANAT was longer-lived than the wild-type rat
MLSrAANAT3f in HEK293T cells (compare Fig. 7A with Fig.
6A). Interestingly, themutant human (M)PThAANAT3f was less
stable than the wild-type human MLSrAANAT3f during the
course of a 2-h chase in HEK293T cells (Fig. 7, A and C).
We also asked whether the (relatively slow) degradation of
thewild-type human (M)SThAANAT3f (Fig. 7,A andC) required
both its lysine-dependent ubiquitylation and the proteasome.
CHX-chases were carried out with (M)SThAANAT3ha and its
lysine-lacking mutant (M)SThAANAT3haKzero. The latter protein
was stable during the chase (t1⁄2  4 h), whereas wild-type
(M)SThAANAT3ha exhibited a weak but observable instabil-
ity (Fig. 7, B and D). Treatment with the MG132 proteasome
inhibitor increased the level of the wild-type human
(M)SThAANAT3ha during CHX-chase, confirming proteasome
dependence of its (slow) degradation (Fig. 7, B (lanes 3 and 7)
and D).
Discussion
The23-kDa AANAT (also called serotonin N-acetyltrans-
ferase) is apparently universal among animals and is present in
plants as well. AANAT converts the neurotransmitter sero-
tonin to NAS, a regulatory compound in its own right and the
immediate precursor of melatonin, a circulating hormone that
regulates sleep and other circadian processes in vertebrates.
The levels of melatonin and NAS are modulated by oscillatory
circadian circuits and also impact those circuits, in addition to4 J.-H. Oh, B. Wadas, and A. Varshavsky, unpublished data.
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other effects of these compounds (see the Introduction). Hence
the importance of temporal control of the AANAT enzyme.
The expression of AANAT is regulated through both transcrip-
tional and post-translational mechanisms. Details of these
mechanisms differ among vertebrates. In addition, although
AANATenzymes fromdifferent species are highly sequelogous
(71) throughout their ORFs, the sequences of the first10 res-
idues of AANAT tend to differ even among relatively closely
relatedmammals, let alone other animals (Fig. 1C). This pattern
of variation suggests a blend of adaptive (function-linked, nat-
ural selection-based) changes in N-terminal sequences of
AANATs versus an unknown (extent-wise) but apparently
strong flux of quasi-neutral, drift-mediated changes of these
N-terminal sequences on evolutionary time scales.
In the present study, we approached the proteolysis-based
regulation of rat and human AANATs (Fig. 1C) by expressing
them and theirmutants not only inmammalian cells but also in
the yeast S. cerevisiae. This strategy made possible the use of
yeast genetics to illuminate specific proteolytic pathways
involved, in parallel with experiments in mammalian cells.
We found that the wild-type rat AANAT (MLSrAANAT) is
targeted for degradation by two complementary branches of
the N-end rule pathway. Specifically, we showed that the Nt-
acetylated Ac-MLSrAANAT is destroyed through the recogni-
tion of its Nt-acetylated N-terminal Met residue by the Ac/N-
end rule pathway, whereas the non-Nt-acetylatedMLSrAANAT
is targeted for degradation by the Arg/N-end rule pathway,
which recognizes the unacetylated N-terminal Met-Leu
sequence of MLSrAANAT.
The N-terminal sequence of the wild-type human
(M)SThAANAT ((Met)-Ser-Thr) is different from theMet-Leu-
Ser sequence of rat MLSrAANAT (Fig. 1C). We found that the
wild-type human (M)SThAANAT is considerably longer-lived
than its rat MLSrAANAT counterpart and does not appear to be
an efficaciousN-end rule substrate. Together, these and related
results (Figs. 2–7) indicated both a major involvement of the
N-end rule pathway in the control of rodent (specifically rat)
AANAT and substantial differences in the regulation of rodent
and humanAANATs that stem from differences in their N-ter-
minal sequences.
The observed co-targeting of the two “complementary”
forms of the rat MLSrAANAT by the two “complementary”
branches of the N-end rule pathway (Figs. 2 and 3) is in agree-
ment with the earlier finding that the N-terminal region of
MLSrAANAT, and specifically its Leu-2 residue, are an impor-
tant determinant of the observed metabolic instability of this
AANAT (37). The cited study also suggested that either the Lys
residues of MLSrAANAT or its surface-exposed Cys residues
were not essential for its proteasome-mediated degradation
(37). In the presentwork, we compared the degradation ofwild-
type MLSrAANAT and its lysine-lacking MLSrAANAT3haKzero
mutant using CHX-chases. Our results showed that the C-ter-
minally triple-HA-tagged MLSrAANAT3haKzero mutant was com-
pletely stabilized in humanHEK293T cells, in contrast to insta-
bility of wild-type MLSrAANAT, indicating that at least some
Lys residues of MLSrAANAT were required for its degradation
(Fig. 6, B and D).
A possible explanation of the above discrepancy stems from
different choices of C-terminal epitope tags in the earlier and
the present study. Specifically, Huang et al. (37) employed
MLSrAANATC-terminally taggedwith c-Myc epitope (EQKLI-
SEEDL), which contains a Lys residue. In the present work, we
used a triple-HA tag, which lacks Lys residues (the sequence of
FIGURE 7. Degradation of the wild-type human (M)SThAANAT and its
mutants in human HEK293T cells. The test proteins were expressed in
HEK293T cells using a plasmid bearing the (weakened) PCMVt1 promoter (see
“Results” and see Fig. 5, A–C). A, lane 1, fluorescently labeled molecular mass
markers (LI-COR), with their masses, in kDa, indicated on the left. CHX-chases
were performed at 37 °C for the indicated times in HEK293T cells with
the wild-type human (M)SThAANAT3f (lanes 2–5) and with its mutant
(M)PThAANAT3f (lanes 6–9). B, lane 1, fluorescently labeled molecular mass
markers, with theirmasses, in kDa, indicated on the left. Lane 2, HEK293T cells
were transformed with vector (V) alone (control). CHX-chases were per-
formed at 37 °C for the indicated times in HEK293T cells with the wild-type
human (M)SThAANAT3ha (lanes 3–6) and with its lysine-lacking mutant
(M)SThAANAT3ha
Kzero (lanes 8–11). Lanes 7 and 12, same as lanes 6 and 11, except
that theMG132 proteasome inhibitor was present during a 4-h CHX-chase in
each case (see “Experimental Procedures”). Thebands of actin andAANATare
indicated on the right. Asterisks on the right in A and B denote a protein band
(possibly the same protein and possibly a derivative of AANAT) that reacted
withboth anti-FLAGantibody inA andanti-HAantibody inB.C, quantification
of data in A. D, quantification of data in B. E, quantification of data in Fig. 6B
(right), similar to the analogousquantifications described in the legend to Fig.
6, C and D. All quantified CHX-chase assays were carried out at least three
times and yielded results within 10% of the data shown.
Degradation of AANAT by the N-end Rule Pathway
AUGUST 12, 2016•VOLUME 291•NUMBER 33 JOURNAL OF BIOLOGICAL CHEMISTRY 17189
 at PO
STECH
 on June 20, 2019
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
single HA is YPYDVPDYA). Previous analyses of N-degrons
have shown that the targeting apparatus of the Arg/N-end rule
pathway selects a substrate’s internal lysine as a polyubiquity-
lation site through a process in which different (spatially com-
peting, conformationally mobile) Lys residues can be chosen
stochastically, depending on their ability to become transiently
close to the substrate-bound E2-E3 complex (41, 51, 86). Thus,
the presence of a Lys residue in theC-terminal c-Myc epitope of
the earlier study (37)might have rendered the otherwise lysine-
lacking MLSrAANAT mutant still targetable by the N-end rule
pathway. Indeed, tellingly, our initial experiments with lysine-
lackingmutants of MLSrAANAT have employed, inadvertently,
a lysine-containing C-terminal FLAG tag instead of the lysine-
lacking HA tag. Remarkably, the otherwise lysine-lacking but
FLAG-taggedMLSrAANAT3fKzeromutant was found to be unsta-
ble (Figs. 6B (right) and 7E), in contrast to the actually (com-
pletely) lysine-lacking, HA-tagged MLSrAANAT3haKzero mutant
(Fig. 6, B (left) and D), in agreement with the above tag-based
explanation.
In addition to polyubiquitylation and degradation, AANAT
is also regulated through a site-specific phosphorylation, a
modification that stimulates the binding of AANAT to at least
one of the 14-3-3 chaperone-like proteins (they are encoded by
a family of several 14-3-3 genes in mammals). This interaction
with 14-3-3 both protects (phosphorylated) AANAT from deg-
radation and enhances its catalytic activity. Rat, human, and
other AANATs contain two previously mapped phosphoryla-
tion sites, Thr-29 and Ser-203 (position numbers refer to the
sequence of rat MLSrAANAT). Phosphorylation at Thr-29 is
conserved in all examined mammalian AANATs (31). This
phosphorylation, by PKA and/or by PKC, augments the inter-
action between AANAT and 14-3-3 both in vitro and in vivo (1,
5, 37). By expressing AANATs not only inmammalian cells but
also in the heterologous setting of S. cerevisiae, we could ana-
lyze the degradation of AANATs in the possible absence of
phosphorylation at Thr-29 (or its equivalent) and also in the
possible absence of AANAT interactions with 14-3-3 proteins.
Whereas S. cerevisiae has two 14-3-3 proteins (87), there is no
evidence, so far, that bears on their binding, in vivo, to a mam-
malian AANAT.
Our attempts to observe a phosphorylation-induced in vivo
binding of the wild-type rat MLSrAANAT either to an endoge-
nous yeast 14-3-3 protein or to the (overexpressed) human
14-3-3 protein were unsuccessful so far, despite a variety of
tried approaches.5Nevertheless, the likely conceptual benefit of
achieving a phosphorylation-inducible interaction between a
mammalian AANAT and a specific 14-3-3 protein, in a setting
of greatly reduced complexity of 14-3-3s (in comparison with
the large set of their mammalian counterparts), justifies further
work in this direction. 14-3-3 proteins are abundant, broadly
expressed, multifunctional chaperone-like proteins that mod-
ulate catalytic activities of enzymes to which 14-3-3s bind and
also regulate protein-protein interactions and subcellular tar-
geting of specific proteins (88–90). It is possible, indeed likely,
that 14-3-3 proteins may bind, in a regulated manner, not only
to, for example, rat MLSrAANAT but to other N-end rule sub-
strates as well, thereby controlling the rates of degradation of
such substrates in ways that remain to be explored.
Recently, the naturally occurring mutant human protein
RGS2Q2L was shown to be a conditionally short-lived substrate
of both the Ac/N-end rule pathway and the Arg/N-end rule
pathway (60). This clinically relevant mutant of RGS2 (a nega-
tive regulator of specific G proteins) was identified in a cohort
of hypertensive Japanese patients (91) (also see the Introduc-
tion). In the present study, we demonstrated that the otherwise
unrelated ratMLSrAANATprotein, whoseN-terminalMet-Leu
sequence is identical to that of RGS2Q2L, is also targeted for
degradation by both branches of the N-end rule pathway (Figs.
1 and 2). These results further expanded the set of identified
mammalian N-end rule substrates of the Met- type.
Interestingly, RGS2, an N-end rule substrate (60), has been
identified as a physiologically relevant inhibitor of theAANAT-
dependent melatonin production (92). Light-stimulated, nor-
epinephrine-induced increases in the levels and activity of
AANAT are mediated by G-protein-coupled adrenergic recep-
tors, whose activation increases intracellular cAMP, and subse-
quently the levels of AANAT as well, at least in part through an
increased phosphorylation of AANAT and the resulting induc-
tion of its binding to protective 14-3-3 proteins (5, 28). While
acting to increase the levels and activity of AANAT (which is
required for the synthesis of NAS and melatonin), cAMP also
acts as a negative feedback inhibitor of melatonin production
through up-regulation of Rgs2 transcription. The resulting
increase in RGS2 inhibits the activity of G proteins that are
coupled to the norepinephrine-responsive receptor, a negative
feedback circuit that acts to decrease cAMP levels (92).
AANAT results of the present study, together with the earlier
evidence that RGS2 is both a conditionally short-lived N-end
rule substrate and an (indirect) down-regulator of AANAT (60,
92), indicate that the N-end rule pathway is a pleiotropic con-
troller of circuits that either directly or indirectly modulate
AANAT.
Previous studies of AANAT demonstrated that its transcrip-
tional regulation can be different in different species, but it has
been conjectured that mechanisms and regulation of AANAT
degradationwould bemore conserved in evolution (11, 34–36).
As shown in the present study, the rates of degradation of the
human and rat AANAT proteins are quite different. Moreover,
whereas rat MLSrAANAT is destroyed by the N-end rule path-
way (Figs. 2 and 6), human (M)SThAANAT is substantially
resistant to this pathway (Figs. 3 and 7). Nevertheless, if the
identification of RGS2 as a feedback inhibitor of AANAT
expression in the rat pineal gland (92) could also be shown to
extend to human RGS2, the N-end rule pathway would be a
regulator of AANAT in humans as well, albeit an indirect one.
An earlier study of human (M)SThAANAT described its
apparent degradation by the proteasome but did not detect its
ubiquitylation (33). In that study, the instability of human
(M)SThAANAT was inferred from increases in its steady-state
levels in the presence of a proteasome inhibitor. In the present
work, we employed, in particular, CHX-chases to show that
although human (M)SThAANAT is degraded by the protea-
some, it is substantially longer-lived than rat MLSrAANAT5 B. Wadas and A. Varshavsky, unpublished data.
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under the same conditions, either in mammalian cells or in
S. cerevisiae (Figs. 2–7).
In sum, our results indicate both a major involvement of the
N-end rule pathway in the control of rodent AANATs and sub-
stantial differences in the regulation of rodent and human
AANATs that stem from differences in their N-terminal
regions (Fig. 1C).What is the cause of the remarkable variability
of N-terminal sequences of AANATs during mammalian (and,
more generally, animal) evolution? Given the extent of variabil-
ity (Fig. 1C), it is nearly certain that a substantial fraction of
these changes resulted from a quasi-neutral, unselected genetic
drift (93). At the same time, the broad and biologically relevant
variation in detailed circadian rhythms among different animal
species (due to specific ecological and physiological adapta-
tions) and the role of AANAT in these rhythms suggest that the
seeming randomness of the N-terminal sequences of AANATs
(Fig. 1C) may be obscuring, so far, a set of adaptive (selected)
changes in these sequences over evolutionary time scales.
Experimental Procedures
Yeast Strains, Media, and Genetic Techniques—Standard
yeast genetic techniques were used (94–96). S. cerevisiae strain
BWY29 was constructed by transforming the strain CHY345
(ubr1::LEU2 in the strain background of BY4742) with a PCR-
amplified DNA fragment that encoded the selection marker
KanMX6 (making cells resistant to kanamycin) and was tar-
geted to the 5	- and 3	-flanking regions of the NAA10 gene,
thereby replacing the ORF of NAA10 with KanMX6 (Table 1).
S. cerevisiae strain JOY487 was made by transforming BY4742
with a PCR-amplified DNA fragment that encoded the natNT2
marker (making cells resistant to nourseothricin) and was tar-
geted to the 5	- and 3	-flanking regions of PDR5, thereby
replacing the ORF of PDR5 with natNT2 (Table 1). The result-
ing pdr5 cells were used in experiments that involved the
MG132 proteasome inhibitor (Fig. 4, A and B). Other S. cerevi-
siae strains used in this study were constructed previously and
are cited in Table 1. S. cerevisiae were transformed using the
LiAc/PEG method (97). S. cerevisiae media included YPD
medium, synthetic complete medium, and synthetic drop-out
medium (95, 96).
Plasmids, cDNAs, and Primers—Turbo Escherichia coli (New
England Biolabs) was used for cloning and maintaining plas-
mids. Phusion High-Fidelity DNA polymerase (New England
Biolabs) was used for carrying out PCR. Nucleotide sequences
of all plasmids were verified by DNA sequencing. The plasmids
and PCR primers used in this study are described in Tables 2
and 3, respectively.
The low copy pBW105, pBW106, pBW107, and pBW209
plasmids expressed the wild-type rat MLSrAANAT3f (wild-type
rat AANATbearing theN-terminal sequenceMet-Leu-Ser and
C-terminally tagged with a triple-FLAG epitope) and its N-
terminal mutants (M)SIrAANAT3f, (M)SMLSrAANAT3f, and
(M)PLSrAANAT3f, respectively, from the PGAL1 promoter. To
construct these plasmids, the rat Aanat ORF was amplified
from pCISII-rAANAT (98), using primers BW2394, BW240,
BW241, BW412, BW243, and BW244 (Table 3). The resulting
PCRproductswere digestedwith EcoRI andHindIII and cloned
in EcoRI/HindIII-cut pRS416GAL1.
The low copy pBW135 and pBW394 plasmids expressed the
wild-type rat MLSrAANAT C-terminally tagged with the tri-
ple-HA epitope (MLSrAANAT3ha) and its Lys-83 Arg mutant
MLSrAANAT3haK8R, respectively, from the PCUP1 promoter. To
construct these plasmids, the rat Aanat ORF was amplified
from pCISII-rAANAT (98) using primers BW339, BW704,
BW338, BW339, and BW340 (Table 3). The amplified DNA
fragments were digested with EcoRI and XhoI and cloned in
EcoRI/XhoI-cut pRS313CUP1 (59, 99).
The low copy pBW395 and pBW419 plasmids expressed the
wild-type human (M)SThAANAT C-terminally tagged with a
triple-FLAG epitope ((M)SThAANAT3f) and its N-terminal
mutant (M)PThAANAT3f, respectively, from the PGAL1 pro-
moter. To construct these plasmids, the human AANAT ORF
from Genscript clone OHu55705 (Genscript, Piscataway, NJ)
was amplified using primers BW705, BW711, BW712, and
BW244 or primers BW771, BW711, BW712, and BW244,
respectively (Table 3). The PCR-amplified DNA fragments
were digested with EcoRI and HindIII and were ligated into
EcoRI/HindIII-cut pRS416GAL1 (99). All final DNA constructs
were verified by DNA sequencing. See items i–x at the begin-
ning of “Results” for information about rat and humanAANAT
notations.
For expression of the above AANAT-encoding ORFs in
humanHEK293T cells, theseORFswere cloned into amodified
expression vector derived from pcDNA3. That (modified) vec-
tor, termed pcDNA3CMVt1, contained a truncated (weakened)
version of the PCMV promoter, termed PCMVt1. The
pcDNA3CMVt1 plasmid was constructed by amplifying, using
PCR, the 276-bp fragment that encompassed 104 bp at the
3	-end of the PCMV promoter region in pcDNA3, its T7 pro-
moter site, and its multiple cloning site, using primers BW375
and BW376 (Table 3). The amplified DNA fragment was
digested with NruI and XbaI and ligated into NruI/XbaI-cut
pcDNA3, yielding the plasmid pBW173 (Table 2). Its truncated
PCMVt1 promoter retained several proximal promoter ele-
ments, including the consensus NFB site, the CREB-binding
site, and two SP1/SP3-binding sites, but lacked more distal
enhancer elements. This resulted in a 70% lower activity of
the PCMVt1 promoter in HEK293T cells, in comparison with
PCMV (Fig. 5, A–C).
The pcDNA3CMVt1-based plasmids pBW206, pBW211,
pBW212, and pBW213 expressed, in HEK293T cells, either the
wild-type rat MLSrAANAT3f or its N-terminal mutants
(M)SIrAANAT3f, (M)SMLSrAANAT3f, and (M)PLSrAANAT3f
from the PCMVt1 promoter. To construct these plasmids,Aanat
ORFs were amplified from the plasmids pBW105, pBW106,
TABLE 1
S. cerevisiae strains used in this study
Strains Relevant genotypes
Source or
reference
BY4742 MAT his3-1 leu2-0 lys2-0 ura3-0 can1-100 Open Biosystems
BY15470 naa30::kanMX6 in BY4742 Open Biosystems
BY10976 naa10::KanMX6 in BY4742 Open Biosystems
BY17299 doa10:KanMX6 in BY4742 Open Biosystems
CHY345 ubr1::LEU2 in BY4742 Ref. 82
CHY346 ubr1::LEU2 doa10:KanMX6 in BY4742 This study
BWY29 naa10::kanMX6 ubr1::LEU2 in BY4742 This study
CHY349 naa30::kanMX6 ubr1::LEU2 in BY4742 Ref. 40
JOY487 naa30::natNT2 in BY4742 This study
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pBW107, and pBW209 using primers BW352, BW353, BW354,
BW413, and BW355, respectively (Table 3). The amplified
DNA fragments were digested with EcoRI andXhoI and ligated
in EcoRI/XhoI-cut pBW173 (Table 2). All pcDNA3-based con-
structs designed for expression inHEK293T cells contained the
Kozak sequence 5	-ACC immediately upstream of the start
codon.
pBW477, which expressed the MLSrAANAT3ha from the
PCMVt1 promoter, was constructed by using pBW135 as a PCR
template and the primers BW352/BW340. The resulting PCR-
amplified DNA fragment was digested with EcoRI and XhoI
and ligated into EcoRI/XhoI-cut pBW173 (Table 2). pBW478
expressed MLSrAANAT3haKzero (i.e. the lysine-lacking derivative
of MLSrAANAT3ha). It was constructed by using pBW135 as a
PCR template to generate four separate DNA fragments con-
taining lysine-to-arginine mutations. The primer pairs were
704/784, 785/786, 787/788, and 789/340 (Table 3). These frag-
ments were then assembled into a contiguous ORF using PCR.
The resulting DNA fragment, encoding lysine-to-arginine
mutations at each of the four lysines contained in the wild-type
rat MLSrAANAT3f, was digested with EcoRI and XhoI, and
ligated into EcoRI/XhoI-cut pBW173.
pBW466 and pBW467, the pcDNA3-based counterparts of
pBW395 and pBW419 (Table 2) were generated by PCR using
TABLE 2
Plasmids used in this study
Plasmid Description Source or reference
pcDNA3 Invitrogen
pCISII-rAANAT rAANAT in pCISII Ref. 98
pRS313Cup1 pRS313 containing the PCUP1 promoter Varshavsky laboratory collection
pRS416Gal1 pRS416 containing the PGAL1 promoter Varshavsky laboratory collection
pBW105 MLSrAANAT3f in pRS416 with PGal1 This study
pBW106 (M)SIrAANAT3f in pRS416 with PGal1 This study
pBW107 (M)SMLSrAANAT3f in pRS416 with PGal1 This study
pBW135 MLSrAANAT3ha in pRS313 with PCup1 This study
pBW173 pcDNA3 (PCMVt1) This study
pBW206 MLSrAANAT3f in pcDNA3 (PCMVt1) This study
pBW209 (M)PLSrAANAT3f in pRS416 with PGal1 This study
pBW211 (M)SMLSrAANAT3f in pcDNA3(PCMVt1) This study
pBW212 (M)SIrAANAT3f in pcDNA3(PCMVt1) This study
pBW213 (M)PLSrAANAT3f in pcDNA3(PCMVt1) This study
pBW394 MLSrAANAT3haK8R in pRS416 with PGal1 This study
pBW395 (M)SThAANAT3f in pRS416 with PGal1 This study
pBW419 (M)PThAANAT3f in pRS416 with PGal1 This study
pBW466 (M)SThAANAT3f in pcDNA3(PCMVt1) This study
pBW467 (M)PThAANAT3f in pcDNA3(PCMVt1) This study
pBW477 MLSrAANAT3ha in pcDNA3 (PCMVt1) This study
pBW478 MLSrAANAT3haKzero in pcDNA3 (PCMVt1) This study
pBW481 (M)SThAANAT3f in pcDNA3(PCMVt1) This study
pBW482 (M)SThAANAT3haKzero in pcDNA3(PCMVt1) This study
TABLE 3
PCR primers used in this study
Primer Sequence
BW239 5	-CCTTGAATTCATACCCATGTTGAGCATCCA-3	
BW240 5	-CCTTGAATTCATACCCATGAGCATCCA-3	
BW241 5	-CCTTGAATTCATACCCATGAGCATGTTGAGCA-3	
BW243 5	-CCTTTCCTTGTAGTCGGATCCACCGCAGCCACTGTT-3	
BW244 5	-CCTTAAGCTTACTTGTCATCGTCGTCCTTGTAGTCGG-3	
BW335 5	-TTGAATTCATGTTGAGCATCCACCCC-3	
BW338 5	-GTATGGGTAGCAGCCACTGTTCC-3	
BW339 5	-CAGTGGCTGCTACCCATACGATG-3	
BW340 5	-TTCTCGAGTCAAGCGTAATCTGGAACGTC-3	
BW352 5	-AATTGAATTCACCATGTTGAGCATCC-3	
BW353 5	-AATTGAATTCACCATGAGCATCCACC-3	
BW354 5	-AATTGAATTCACCATGAGCATGTTGA-3	
BW355 5	-AATTCTCGAGTTACTTGTCATCGTCG-3	
BW375 5	-TTAATCTAGATGCATGCTCGAGC-3	
BW376 5	-CGTTAATCGCGACCAAAATCAACGGGACTTTC-3	
BW412 5	-TTGAATTCATGCCCTTGAGCATCCACCCC-3	
BW705 5	-TTGAATTCATACCCATGTCCACGCAGAGCACCCACCCCCTGAAACCTGA GGCCCCACGTCTGCCACCTGGGATC-3	
BW711 5	-CTTATAGTCACCAGAACCAGAGCAGCCGCTGTTCCTGCGCAGG-3	
BW712 5	-CAGGAACAGCGGCTGCTCTGGTTCTGGTGACTATAAGGATG-3	
BW771 5	-TTGAATTCATACCCATGCCAACGCAGAGCACCCACCCCCTGAAACCTG AGGCCCCACGTCTGCCACCTGGGATC-3	
BW784 5	-CTGAGTAAGTCTCTCTCTGTCCCAAAGTGAACC-3	
BW785 5	-GGTTCACTTTGGGACAGAGAGAGACTTACTCAG-3	
BW786 5	-CAGCAGGACGGAGCCTCTGCCCTGCTGCCGGAAG-3	
BW787 5	-CTTCCGGCAGCAGGGCAGAGGCTCCGTCCTGCTG-3	
BW788 5	-GGCCTGGAAACCAAATCTCTCATAGAAGGGCAC-3	
BW789 5	-GTGCCCTTCTATGAGAGATTTGGTTTCCAGGCC-3	
BW866 5	-TTGAATTCACCATGTCCACGCAGAGCACCCACCCCC-3	
BW867 5	-TTGAATTCACCATGTCCACGCAGAGCACCCACCCCCTGAGACCTGAGGC-3	
BW868 5	-TTGAATTCACCATGCCAACGCAGAGCACCCACCCC-3	
BW884 5	-TTAAGAATTCACCATGTCCACGCAGAGCACC-3	
BW885 5	-GTCAGGAACATCGTATGGGTAGCAGCCGCTGTTCCTGCGCAGG-3	
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pBW395 and pBW419 as templates and the primers BW866/
BW355 and BW868/BW355, respectively (Table 3). PCR-am-
plified DNA fragments were digested with EcoRI and XhoI and
ligated into EcoRI/XhoI-cut pBW173 (Table 2).
Cell Culture—The HEK293T cell line (derived from human
embryonic kidney cells) was obtained from American Type
Culture Collection (ATCC, Manassas, VA) and was grown at
37 °C in 5% CO2 in DMEM supplemented with 10% FBS (Gem-
ini Bio-Products, West Sacramento, CA) and penicillin/strep-
tomycin (100 units/ml; Hyclone). Cells were transfected using
Lipofectamine-2000 (Invitrogen) according to the manufactu-
rer’s protocol.
Antibody Specific for the Nt-acetylated Form of Rat AANAT
(MLSrAANAT)—Unpurified rabbit polyclonal antisera against
the synthetic peptide Ac-MLSIHPLKPEAC were produced by
Abgent (San Diego, CA) essentially as described for other pep-
tide-mediated polyclonal antibodies produced in studies by the
Varshavsky laboratory (e.g. see Refs. 59 and 66). The sequence
of theNt-acetylated peptide immunogen comprised the first 11
residues of MLSrAANAT (Fig. 1C; see below), followed by the
C-terminal Cys residue that was used to conjugate the peptide
to keyhole limpet hemocyanin carrier protein. The antiserum
was affinity-purified in two sequential steps. First, the antibody
sample was incubated with the C-terminally immobilized orig-
inal immunogen Ac-MLSIHPLKPEAC. The peptide-bound
fraction was eluted as described previously (59, 66). That fraction
was thereafter “negatively” purified against the otherwise identical
but non-Nt-acetylated immobilized MLSIHPLKPEAC peptide
(the peptides were immobilized using a sulfhydryl-coupling
resin (Abgent)), collecting, this time, the unbound fraction.
The resulting antibody sample was used to detect, selectively,
the Nt-acetylated form of rat AANAT (see “Results” and Fig.
5D). The fraction of once purified antibody that was bound to
the non-Nt-acetylated MLSIHPLKPEAC peptide was also
eluted and retained and was used as an antibody that could
recognize the N-terminal region of rat AANAT irrespective of
its Nt-acetylation state.
Cycloheximide Chase Assay in S. cerevisiae—CHX-chase
assays in S. cerevisiae were performed largely as described (39,
59). Briefly, S. cerevisiae cells were grown in overnight cultures,
and expression of epitope-tagged test proteins was induced by
the addition of 2% galactose (for plasmids containing the PGAL1
promoter) or 0.1mMCuSO4 (for plasmids containing the PCUP1
promoter (100)). 3 h post-induction, CHX was added to a final
concentration of 0.1mg/ml. Samples were collected at the indi-
cated time points, centrifuged at 11,200
 g for 2 min to pellet
the cells, and snap-frozen in liquid nitrogen. Proteins were
extracted by resuspending the pellets in 1ml of 0.2MNaOHand
incubating on ice for 20min (101). Cells were then pelleted and
resuspended in 50 l of SUMEB loading buffer (1% SDS, 8 M
urea, 10mM EDTA, 0.01% bromphenol blue, 10mMMOPS, pH
6.8), followed by heating at 95 °C for 10min. Samples were then
centrifuged at 11,200 
 g for 5 min, followed by SDS-PAGE
(with 10 l loaded per well) using 4–12% NuPAGE gels (Invit-
rogen). Fractionated proteins were transferred onto nitrocellu-
lose membranes for immunoblotting analyses (see below).
Cycloheximide Chase Assay in Mammalian Cell Lines—
HEK293T cells were transfected with 4g of plasmid DNA per
well (10-cm2 surface area) in 6-well plates using Lipofectamine-
2000 (Invitrogen) according to the manufacturer’s protocol.
24 h after transfection, cells were treatedwithCHX (0.1mg/ml)
to initiate a chase. All cells from one well were collected at each
indicated time point by washing cells quickly in ice-cold PBS
and then rapidly scraping cells into 1.5-ml tubes, pelleting them
by centrifugation at 4 °C (at 10,000 
 g for 1 min), and snap-
freezing the pellets in liquid nitrogen. Cells in these samples
were later lysed by the addition of 0.2 ml of “mammalian lysis
buffer” (1% Nonidet P-40, 0.15 M NaCl, 50 mM Tris-HCl, pH
7.5) containing 1
RocheComplete Protease InhibitorMixture
and brief sonication, followed by centrifugation at 11,200 
 g
for 10min. Total protein concentration in the supernatants was
measured by the bicinchoninic acid (BCA) assay (Thermo
Fisher Scientific). 30 g of total protein in a thus prepared
extract in lithium dodecyl sulfate (LDS)-sample buffer (in a vol-
ume of 45 l) were heated at 70 °C for 10 min, followed by
LDS-PAGE on a 4–12% BisTris NuPAGE gel (Invitrogen) and
subsequent transfer onto nitrocellulose membranes for
immunoblotting.
Immunoblotting—Following electrophoresis, proteins sepa-
rated by LDS-PAGE or SDS-PAGE, as indicated above, were
electroblotted on nitrocellulose membranes by iBlot (Invitro-
gen; Program 3; 7-min transfer). Membranes were blocked and
thereafter incubated with the appropriate primary antibody,
followed by LI-COR IRDye-conjugated secondary antibodies.
IRDye fluorescencewas detected using anOdyssey 9120 system
(LI-COR, Lincoln, NE), facilitating quantification of immuno-
blots. All quantification was done on LI-COR Odyssey soft-
ware. Antibodies used include anti-FLAG mouse monoclonal
antibody (clone M2; 1:2,000 dilution; Sigma-Aldrich), anti--
tubulin mouse monoclonal antibody (clone B-5-1-2; 1:10,000
dilution; Sigma-Aldrich), anti-HAmousemonoclonal antibody
(clone HA-7; 1:2,000 dilution; Sigma-Aldrich), anti--actin
mouse monoclonal antibody Ab8224 (1:4,000 dilution; Abcam,
Cambridge, UK), and anti-14-3-3 rabbit monoclonal antibody
EPR6379 (1:100,000 dilution; Abcam).
Immunoprecipitation of Polyubiquitylated AANAT—
HEK293T cells were transfected with 4g of plasmid DNA per
well (10-cm2 surface area) in 6-well plates using Lipofectamine-
2000 (Invitrogen) according to the manufacturer’s protocol.
24 h after transfection, cells were treated with the proteasome
inhibitor MG132 (final concentration of 10 M; AG Scientific,
San Diego, CA) or with an equivalent volume of DMSO in
which the 10 mM stock solution of MG132 was made, as indi-
cated. 6 h post-treatment, cells were collected by washing them
quickly on a plate in ice-cold PBS and then rapidly scraping cells
into 1.5-ml tubes and pelleting themby centrifugation at 4 °C at
10,000 
 g for 1 min. Pellets were resuspended in 0.1 ml of
buffer containing 1% SDS and 50 mM Tris (pH 7.5) and heated
at 95 °C for 10 min. After boiling, samples were diluted with 1
ml of buffer TNN (0.5% Nonidet P-40, 0.25 M NaCl, 5 mM
EDTA, 50 mM Tris, pH 7.5) containing 1
 Roche Complete
Protease Inhibitor Mixture, 20 mM N-ethylmaleimide (Sigma-
Aldrich), and 50 M PR-619 (LifeSensors, Malvern, PA) as
inhibitors of deubiquitylation. 25l of anti-HAmagnetic beads
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were then added to each sample, and samples were incubated at
4 °C overnight, followed by three washes in TNN, 1 wash in 10
mMTris-HCl, pH8.5, and elutionwith 50l of 0.1M glycine, pH
2.0, by incubation at room temperature for 10 min. After elu-
tion, the samples were neutralized and then heated at 70 °C in
LDS-PAGE sample buffer, followed by LDS-PAGE on a 4–12%
NuPAGE gel. Fractionated proteins were then electroblotted
onto nitrocellulose membranes. The resulting membranes
(containing transferred proteins) were autoclaved as described
previously (102) before “downstream” immunoblotting proce-
dures with either anti-HA or anti-ubiquitin antibodies to
increase the sensitivity of detection of polyubiquitin chains.
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